Background
It is known that many interstitial lung diseases (ILDs) can lead to lung fibrosis at their late stages [1] .
ILD is associated with attacks of acute respiratory failure (ARF) that may happen at any time during the course of the disease and is linked to increased morbidity and mortality [2] . Those attacks may be precipitated by known etiologies, for example, respiratory tract infections and acute cardiac failure. When the cause of this deterioration could not be identified, it is called acute exacerbation of lung fibrosis [3, 4] .
Patients with acute exacerbation of ILD can be supported by mechanical ventilation. But, this can lead to a condition known as ventilator-induced lung injury [5] [6] [7] [8] .
Recently, in order to minimize mechanical ventilation complications such as ventilator-associated pneumonia and for improving outcomes in ARF due to some certain causes, noninvasive ventilation (NIV) is studied [9, 10] . But the results are conflicting [11] [12] [13] [14] [15] .
High-flow nasal oxygen therapy (HFNOT) in which warmed and humidified oxygen is supplied to the nose at flow rates which is up to 60 l/min high, can lead to low levels of positive pressure (2-5 cm H 2 O) in the upper airways. The fraction of inspired oxygen (FiO 2 ) can be adjusted (≤100%) by altering the portion of oxygen in the driving gas mixture [16] [17] [18] [19] . The physiological dead space may be lowered by removing expired carbon dioxide from the upper airway, and this can lead to decreasing the work of breathing and improving in patient compliance [20] . High-flow oxygen has been proven to accomplish better patient oxygenation and compliance than conventional oxygen therapy delivered via a face mask in patients with ARF due to different etiologies [21] [22] [23] [24] [25] [26] .
To our knowledge, HFNOT has not been studied in patients with ILD during attacks of ARF. So, this study aimed to determine the role of HFNOT versus NIV in reducing the rate of endotracheal intubation
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Patients and methods
A total of 70 consecutive patients with ILD admitted to the medical ICU of Najd Consulting Hospital, Saudi Arabia, due to an episode of ARF were included in this prospective study between January 2016 and May 2017. A written consent was obtained from the patients and the institutional review board of the hospital approved the study.
Inclusion criteria
Adult patients with ILD were enrolled in this study if they had a PaO 2 /FiO 2 of less than or equal to 300 mmHg despite oxygen supplementation at a flow rate of greater than or equal to 10 l/min for at least 15 min or if they had manifestation of increased work of breathing, for example, use of accessory muscles of respiration [4, 27] .
Exclusion criteria
Patients were excluded if they were younger than 18 years of age, if they had pneumothorax, an absolute indication for urgent intubation like coma or if they had contraindications to NIV.
Interventions
Patients were randomized to receive either NIV or HFNOT.
We used BiPAP Vision (Respironics Inc., Murrysville, Pennsylvania, USA) for NIV support. Continuous positive airway pressure mode was initiated for NIV and the continuous positive airway pressure level was gradually incremented to 12 cm H 2 O. And we added pressure support if respiratory acidosis (pH<7.35) or if respiratory rate greater than 30 breaths/min was encountered, and FiO 2 was adjusted at the lowest level to maintain a PaO 2 greater than 60 mmHg [4].
In the HFNOT group, the patients were connected to the Optiflow Device System (850 system; Fisher & Paykel, New Zealand) using a large-diameter NC (Optiflow nasal cannula). This system allows delivery of consistent FiO 2 from 0.21 to 1.0, and generates up to 60 l/min flow rates [19] .
NIV or HFNOT were applied until the patient was recovered or was intubated.
The criteria for endotracheal intubation were: disturbed level of consciousness, hemodynamic instability, clinical signs of exhaustion, development of excessive tracheal secretions, or refractory hypoxemia [27] .
The patients were treated medically according to the trigger of exacerbation and the local ICU protocol.
Study outcomes
The need for intubation within 28 days after admission to the ICU was the primary outcome of our study. Secondary outcomes were ICU mortality and the number of days without the need for invasive mechanical ventilation within 28 days of admission [27] .
Statistical analysis SPSS (version 18.0; SPSS Inc., Chicago, Illinois, USA) was used for analyzing the results of this study. Continuous data were expressed as a mean± SD and categorical data expressed as counts (%). Differences of continuous data between groups were evaluated by Mann-Whitney test. Differences of categorical variables between two groups were analyzed using the χ 2 -test or Fisher's exact test where appropriate. A P value was considered statistically significant if it was less than 0.05.
Results
This prospective study included 70 consecutive patients with ILD (25 men and 45 women) admitted to the medical ICU of Najd Consulting Hospital, Riyadh, Saudi Arabia, due to an episode of ARF between January 2016 and May 2017.
The flowchart of the study is illustrated in Fig. 1 . Tables 1 and 2 show no statistically significant difference between the group of patients who received NIV and those who received HFNOT as regards baseline demographic, clinical, and laboratory data. Table 4 illustrates the causes of ARF in all studied patients. The main etiology of ARF was pneumonia which was the diagnosis in 39 (55.7%) patients. Acute exacerbation of fibrosis was present in 21 (30%) Flowchart of the study: ARF, acute respiratory failure; HFNOT, high-flow nasal oxygen therapy; ILD, interstitial lung disease; NIV, noninvasive ventilation. patients. Pulmonary thromboembolism was the diagnosis in five (7.14%) patients and five (7.14%) patients had cardiac failure. Table 5 shows the outcomes of the current study. The rate of endotracheal intubation at day 28 was 22.2% in the NIV group and 20.6% in the HFNOT group with no statistically significant difference (P=0.87). In-hospital mortality was 30.6% in the NIV group and 26.5% in the HFNOT group with no statistically significant difference (P=0.71) .The ventilator-free days was significantly lower in the NIV group when compared with the HFNOT group (16±7 and 20±5; P=0.008, respectively).
Discussion
The results of the current study has shown that the ventilator-free days, in ILD patients with ARF, was significantly higher in the patients who received HFNOT than those who received NIV, but not the need for intubation at day 28 nor in-hospital mortality.
Oxygen supplementation is very essential in clinical medicine since first reported in 1890 [28] . Many modalities for delivering oxygen have been evaluated in spontaneously breathing patients with ARF [29] . The results of the outcome of NIV as regards the avoidance of endotracheal intubation and the improvement in patient outcome are conflicting [11] [12] [13] [14] [15] . Moreover, the use of NIV in type I (hypoxemic) ARF is still doubtful [30] .
HFNOT has been introduced as a potential substitute to NIV or oxygen therapy by the conventional routes [31] . This new technique has the advantage of providing humidified oxygen at a high flow rate of up to 60 l/min via a nasal cannula. Also the high flow rate of oxygen set up low levels of positive endexpiratory pressure. This new modality of providing oxygen is believed to be more tolerable by the patient and may also reduce the work of breathing [31, 32] .
This prospective, randomized study including 70 patients was carried out aiming to assess the clinical outcomes with HFNOT versus NIV for ILD patients during an episode of acute hypoxemic respiratory failure. HFNOT, high-flow nasal oxygen therapy; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NIV, noninvasive ventilation. ILDs are well known to involve many different disorders that can lead to lung destruction by fibrosis [2] . In the current study, the majority of the patients are under the category of idiopathic interstitial fibrosis (IPF) (27%); this agrees with the previous studies which showed that the risk of acute exacerbation in patients with IPF is more common in comparison with non-IPF ILD patients [33] [34] [35] [36] .
Pneumonia was the predominant etiology of ARF among the patients of the present study (55.7%) followed by acute exacerbation of fibrosis (30%). This result is coping with the findings obtained by many other investigators who found pneumonia to be the major cause of ARF in their studies [1, 4, 27, 37] .
Diagnosing acute exacerbation of fibrosis in ILD often comprises a challenge. Several alternative diagnoses such as pulmonary infection, pulmonary embolism, or cardiac failure should be ruled out by carrying out multiple diagnostic tests [2] .
In this study, HFNOT did not result in a decrease in the rate of intubation among patients with ILD during the ARF episode. But, HFNOT allowed for more ventilatorfree days among those patients when compared with NIV. These findings are in agreement with that of Frat et al. [27] , who studied the efficacy of delivering oxygen by nasal cannula at high flow versus supporting ventilation by noninvasive route and the conventional oxygen supplementation in acute hypoxemic respiratory failure. However, contrary to the results of our study Frat et al. [27] showed that HFNOT had a reduction in ICU mortality. The larger number of their studied patients may explain their results as it allowed them to do a post hoc adjusted analysis, which involved only patients with more severe hypoxemia (PaO 2 : FiO 2 : ≤200 mmHg) and resulted a significantly lower intubation rate in the group of patients who were at high flow oxygen than the other two groups. The cumulative effect of this lower intubation resulted in a lower in-hospital mortality [27, 29] . The lower number of our studied patients (n=70) did not allow us to perform that post hoc adjusted analysis for more severe patients like in Frat et al. [27] .Another two recent reports proved the efficacy of HFNOT in lowering the rate of intubation and ICU mortality when compared with NIV [38, 39] . However, both trials are retrospective and included younger immunocompromised patients without the underlying lung pathology.
Previous studies have shown that HFNOT was also accompanied with a higher tolerability, patient comfort, a reduction in the severity of dyspnea.
These results were explained by the humidification and warming of the provided oxygen, which lead to liquefaction of secretions and so avoid atelectasis of the lung and also from generating low levels of positive endexpiratory pressure [16, 17] and dead space reduction [21, 22, 24, 25] .
In conclusion, a therapy with high-flow oxygen by nasal cannula reduced ventilator-free days in patients with fibrotic diffuse ILDs with ARF. Although there was no difference in the rate of need for neither endotracheal intubation nor in-hospital mortality as compared with NIV.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
